Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 10/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.50 |
| ▸ | MET | P08581 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26621561 | 0.89 | INSR (0.50) | INSRALKMETPKMTRIM24 | |
| SCHEMBL30661466 | 0.89 | INSR (0.50) | INSRALKMETPKMTRIM24 | |
| SCHEMBL26621718 | 0.89 | INSR (0.50) | INSRALKMETPKMTRIM24 | |
| SCHEMBL26760204 | 0.83 | BCL6 (0.54) | INSRALKMETBCL6 | |
| SCHEMBL26760849 | 0.80 | INSR (0.44) | INSRALKMETPKMTRIM24 | |
| SCHEMBL31444679 | 0.79 | INSR (0.56) | INSRALKMETTRIM24 | |
| SCHEMBL31442262 | 0.79 | INSR (0.54) | INSRALKMET | |
| SCHEMBL26760961 | 0.79 | INSR (0.45) | INSRALKMETBCL6 | |
| SCHEMBL27072329 | 0.79 | INSR (0.45) | INSRALKMETBCL6 | |
| SCHEMBL27072319 | 0.78 | BCL6 (0.58) | INSRALKBCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | INSR 1256/4885ALK 1471/4885MET 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.